Table 1.
Characteristics of patients with psoriasis who achieved PASI90 at 6 months following biologic therapy initiation in the CorEvitas Psoriasis Registry
| Characteristic | Overall (N = 687) | Bio-naïve (N = 357) | Bio-experienced (N = 330) |
|---|---|---|---|
| Age (years), mean (SD) | 48.8 (15.1) | 47.2 (15.1) | 50.6 (14.9) |
| Gender (female), n (%) | 259 (37.7) | 132 (37.0) | 127 (38.5) |
| Race, n (%) | |||
| White | 510 (74.2) | 265 (74.2) | 245 (74.2) |
| Black | 21 (3.1) | 7 (2.0) | 14 (4.2) |
| Asian | 94 (13.7) | 52 (14.6) | 42 (12.7) |
| Other/unknown | 62 (9.0) | 33 (9.2) | 29 (8.8) |
| Ethnicity (Hispanic), n (%) | 66 (9.7) | 39 (11.0) | 27 (8.3) |
| Health insurance (private), n (%) | 481 (77.2) | 251 (78.4) | 230 (75.9) |
| Employment (full-time), n (%) | 425 (61.9) | 239 (66.9) | 186 (56.4) |
| Smoking history, n (%) | |||
| Never | 359 (52.9) | 192 (54.4) | 167 (51.4) |
| Former smoker | 210 (31.0) | 106 (30.0) | 104 (32.0) |
| Current smoker | 109 (16.1) | 55 (15.6) | 54 (16.6) |
| BMI, n (%) | |||
| Underweight/normal (< 25 kg/m2) | 137 (20.2) | 86 (24.4) | 51 (15.6) |
| Overweight (25 to < 30 kg/m2) | 211 (31.1) | 103 (29.2) | 108 (33.1) |
| Obese (≥ 30 kg/m2) | 331 (48.7) | 164 (46.5) | 167 (51.2) |
| Body weight (kg), mean (SD) | 91.7 (23.9) | 90.1 (24.2) | 93.4 (23.5) |
| Non-cardiovascular comorbidity, n (%)a | 51 (7.4) | 21 (5.9) | 30 (9.1) |
| Cardiovascular comorbidity, n (%)b | 308 (44.8) | 135 (37.8) | 173 (52.4) |
| History of diabetes | 112 (16.3) | 44 (12.3) | 68 (20.6) |
| History of hyperlipidemia | 179 (26.1) | 78 (21.8) | 101 (30.6) |
| History of hypertension | 242 (35.2) | 110 (30.8) | 132 (40.0) |
| History of anxiety or depression, n (%) | 164 (23.9) | 80 (22.4) | 84 (25.5) |
| Psoriasis duration (years), mean (SD) | 15.9 (13.5) | 12.8 (12.5) | 19.2 (13.7) |
| History of PsA, n (%)c | 300 (43.7) | 116 (32.5) | 184 (55.8) |
| PASI > 12, n (%) | 290 (42.2) | 147 (41.2) | 143 (43.3) |
| PASI90–PASI95, n (%)d | 134 (19.5) | 65 (18.2) | 69 (20.9) |
| PASI95–PASI100, n (%)d | 100 (14.6) | 48 (13.5) | 52 (15.8) |
| PASI100, n (%)d | 453 (65.9) | 244 (68.4) | 209 (63.3) |
| Fatigue (VAS-100), mean (SD)d | 20.4 (25.1) | 18.1 (24.7) | 22.8 (25.4) |
| Skin pain (VAS-100), mean (SD)d | 5.6 (13.8) | 4.4 (12.4) | 6.9 (15.0) |
| Itch (VAS-100), mean (SD)d | 11.1 (20.5) | 11.6 (21.5) | 10.5 (19.5) |
| DLQI, mean (SD)d | 1.5 (2.7) | 1.2 (2.2) | 1.9 (3.1) |
| Clinically meaningful skin symptoms, n (%)d,e | 71 (12.6) | 35 (12.2) | 36 (12.9) |
| Concomitant therapy, n (%)f | |||
| Systemic non-biologic therapy | 34 (4.9) | 15 (4.2) | 19 (5.8) |
| Topical therapy | 348 (50.7) | 191 (53.7) | 157 (47.6) |
| Phototherapy | 25 (3.6) | 16 (4.5) | 9 (2.7) |
| Prior systemic non-biologic therapy use, n (%) | 357 (52.0) | 137 (38.4) | 220 (66.7) |
| Systemic biologic therapy class initiated, n (%) | |||
| TNFi | 81 (11.8) | 67 (18.8) | 14 (4.2) |
| IL-17Ai | 285 (41.5) | 110 (30.8) | 175 (53.0) |
| IL-12/23i or IL-23i | 321 (46.7) | 180 (50.4) | 141 (42.7) |
BMI body mass index, DLQI Dermatology Life Quality Index, i inhibitor, IL interleukin, PASI Psoriasis Area and Severity Index, PEST Psoriasis Epidemiology Screening Tool, PsA psoriatic arthritis, SD standard deviation, TNF tumor necrosis factor, VAS visual analog scale
aNon-cardiovascular comorbidities included chronic obstructive pulmonary disease, peptic ulcer disease, lymphoma, and solid tumor cancer (excluding non-melanoma of the skin)
bCardiovascular comorbidities included hyperlipidemia, diabetes, and hypertension
cDetermined by a dermatologist report of PsA or any history of a PEST score of 3 or greater
dCharacteristic was measured at index visit
eDefined as either having ≥ 45 on the skin pain VAS or ≥ 30 on the itch VAS
fOptions are not mutually exclusive, more than one category can be indicated